CA3175419A1 - Diagnostic methods using mir-485-3p expression - Google Patents
Diagnostic methods using mir-485-3p expressionInfo
- Publication number
- CA3175419A1 CA3175419A1 CA3175419A CA3175419A CA3175419A1 CA 3175419 A1 CA3175419 A1 CA 3175419A1 CA 3175419 A CA3175419 A CA 3175419A CA 3175419 A CA3175419 A CA 3175419A CA 3175419 A1 CA3175419 A1 CA 3175419A1
- Authority
- CA
- Canada
- Prior art keywords
- mir
- seq
- nucleotides
- aspects
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014633P | 2020-04-23 | 2020-04-23 | |
| US63/014,633 | 2020-04-23 | ||
| US202063047206P | 2020-07-01 | 2020-07-01 | |
| US63/047,206 | 2020-07-01 | ||
| US202063064305P | 2020-08-11 | 2020-08-11 | |
| US63/064,305 | 2020-08-11 | ||
| PCT/IB2021/053353 WO2021214720A1 (en) | 2020-04-23 | 2021-04-23 | Diagnostic methods using mir-485-3p expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3175419A1 true CA3175419A1 (en) | 2021-10-28 |
Family
ID=78270846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3175419A Pending CA3175419A1 (en) | 2020-04-23 | 2021-04-23 | Diagnostic methods using mir-485-3p expression |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230167502A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4139488A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023522402A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230014705A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115917008A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021260191A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175419A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021214720A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2631292A3 (en) * | 2005-04-29 | 2013-11-20 | The Rockefeller University | Human microRNAs and methods for inhibiting same |
| US20090156459A1 (en) * | 2007-11-16 | 2009-06-18 | Pharmain Corporation | Cationic-Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
| JP6211511B2 (ja) * | 2011-04-18 | 2017-10-11 | ディアミール, エルエルシーDiamir, Llc | miRNAに基づくユニバーサルスクリーニングテスト(UST) |
| US9951330B2 (en) * | 2013-07-11 | 2018-04-24 | The Trustees Of Columbia University In The City Of New York | Micrornas that silence tau expression |
| CN105917005B (zh) * | 2013-11-18 | 2020-09-11 | 迪阿米尔有限责任公司 | 使用来自体液的miRNA检测和监控帕金森病(PD)的方法 |
| WO2018076015A1 (en) * | 2016-10-21 | 2018-04-26 | Thomas Jefferson University | Leveraging the presence or absence of mirna isoforms for recommending therapy in cancer patients |
| WO2018139759A1 (ko) * | 2017-01-26 | 2018-08-02 | 주식회사 바이오오케스트라 | 마이크로 rna를 이용한 알츠하이머병 진단방법 |
| WO2018139819A1 (ko) * | 2017-01-26 | 2018-08-02 | 주식회사 바이오오케스트라 | 마이크로 rna를 이용한 뇌 질환 예방 또는 치료 용도 |
| KR102105016B1 (ko) * | 2019-12-12 | 2020-04-28 | 주식회사 바이오오케스트라 | miR-485-3p를 이용한 알츠하이머병 진단 방법 |
-
2021
- 2021-04-23 WO PCT/IB2021/053353 patent/WO2021214720A1/en not_active Ceased
- 2021-04-23 KR KR1020227041165A patent/KR20230014705A/ko active Pending
- 2021-04-23 AU AU2021260191A patent/AU2021260191A1/en not_active Abandoned
- 2021-04-23 JP JP2022564255A patent/JP2023522402A/ja active Pending
- 2021-04-23 CN CN202180043984.XA patent/CN115917008A/zh active Pending
- 2021-04-23 EP EP21791933.1A patent/EP4139488A4/en not_active Withdrawn
- 2021-04-23 CA CA3175419A patent/CA3175419A1/en active Pending
- 2021-04-23 US US17/997,000 patent/US20230167502A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4139488A4 (en) | 2024-05-22 |
| WO2021214720A1 (en) | 2021-10-28 |
| JP2023522402A (ja) | 2023-05-30 |
| CN115917008A (zh) | 2023-04-04 |
| US20230167502A1 (en) | 2023-06-01 |
| EP4139488A1 (en) | 2023-03-01 |
| AU2021260191A1 (en) | 2022-11-17 |
| KR20230014705A (ko) | 2023-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230256119A1 (en) | Compositions and methods for preparing an alzheimer's disease animal model using microrna | |
| US20230304014A1 (en) | Mirna-485 inhibitor for huntington's disease | |
| US20220081690A1 (en) | Use of mir-204 inhibitor to increase nurr1 protein expression | |
| US20230126157A1 (en) | Mirna-485 inhibitor for gene upregulation | |
| WO2021156833A1 (en) | Use of mirna-485 inhibitors for treating tauopathy | |
| US20230167502A1 (en) | Diagnostic methods using mir-485-3p expression | |
| US20230167447A1 (en) | Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof | |
| WO2022264038A1 (en) | Use of mirna-485 inhibitors for treating inflammasome-related diseases or disorders | |
| US20230121720A1 (en) | Diagnostic methods using pcg-1a expression | |
| US20230119699A1 (en) | Diagnostic methods using sirt1 expression | |
| US20240294908A1 (en) | Use of mirna-485 inhibitors for treating diseases or disorders associated with abnormal nlrp3 expression | |
| US20240117350A1 (en) | Use of mirna-485 inhibitor to regulate psd95, synaptophysin, and caspase-3 expression | |
| WO2022003609A1 (en) | Snp diagnostic methods | |
| WO2024127317A1 (en) | Treating mitochondrial dysfunction with mirna-485 inhibitor | |
| WO2023079499A1 (en) | Use of mir-485 inhibitors to treat age-associated diseases or conditions | |
| WO2023089506A1 (en) | Amplification-free methods for measuring mirna | |
| CN120752337A (zh) | 用于治疗神经疾病的组合物和方法 | |
| EA049701B1 (ru) | Новые векторы на основе аденоассоциированного вируса (aav), векторы aav, со сниженным дезамидированием капсида, а также их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251008 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251208 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260204 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260407 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260604 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260709 |